Prime Medicine, Inc.
PRME
$3.50
$0.205.96%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 647.13% | 739.42% | 550.76% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 647.13% | 739.42% | 550.76% | -- | -- |
| Cost of Revenue | -5.16% | -9.91% | -31.92% | -44.97% | -34.51% |
| Gross Profit | 11.09% | 14.90% | 34.81% | 46.99% | 35.10% |
| SG&A Expenses | -2.03% | 11.55% | 15.19% | 15.61% | 27.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.71% | -0.68% | 5.08% | 7.40% | 21.75% |
| Operating Income | 4.15% | 2.76% | -3.47% | -5.84% | -21.29% |
| Income Before Tax | 9.99% | 8.40% | 1.12% | 1.28% | -27.29% |
| Income Tax Expenses | -- | -- | -335.09% | 100.00% | 100.00% |
| Earnings from Continuing Operations | 9.99% | 8.35% | 1.22% | 1.14% | -27.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.99% | 8.35% | 1.22% | 1.14% | -27.64% |
| EBIT | 4.15% | 2.76% | -3.47% | -5.84% | -21.29% |
| EBITDA | 4.99% | 3.56% | -2.73% | -5.20% | -21.02% |
| EPS Basic | 29.70% | 27.69% | 25.20% | 23.44% | -2.01% |
| Normalized Basic EPS | 25.40% | 23.54% | 22.08% | 17.78% | 1.74% |
| EPS Diluted | 29.70% | 27.69% | 25.20% | 23.44% | -2.01% |
| Normalized Diluted EPS | 25.40% | 23.54% | 22.08% | 17.78% | 1.74% |
| Average Basic Shares Outstanding | 26.52% | 25.20% | 32.04% | 30.37% | 26.13% |
| Average Diluted Shares Outstanding | 26.52% | 25.20% | 32.04% | 30.37% | 26.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |